@article{oai:kanazawa-u.repo.nii.ac.jp:00013385,
 author = {Kato-Motozaki, Yuko and Koma, Kiyonobu and Takahashi, Kazuya and Ishida, Chiho and Ueda, Masami and Kusunoki, Susumu and Yamada, Masahito},
 issue = {7},
 journal = {Internal Medicine},
 month = {Jan},
 note = {Polyethylene glycol-interferon ﾎｱ (PEG-IFNﾎｱ) has been used as the standard treatment for hepatitis C virus (HCV) infection. There have been no previous reports of polyradiculoneuropathy with anti-ganglioside antibodies induced by PEG-IFNﾎｱ-2b. We report a 59-year-old man who developed polyradiculoneuropathy during treatment with PEG-IFN ﾎｱ-2b for chronic HCV infection. Serum levels of anti-asialo-GM1 (GA1) and anti-GM1 antibodies were elevated. Cessation of therapy with double filtration plasmapheresis resulted in marked improvement in his symptoms accompanied by a reduction in the antibody level. PEG-IFN ﾎｱ-2b may induce peripheral neuropathy mediated by anti-GA1 and anti-GM1 antibodies. © 2009 The Japanese Society of Internal Medicine., 金沢大学医薬保健研究域医学系},
 pages = {569--572},
 title = {Polyethylene Glycol Interferon α-2b-induced Immune-mediated Polyradiculoneuropathy},
 volume = {48},
 year = {2009}
}